Innova: GLP-1-friendly food and beverage launches rise by 190%
Innova’s research covering the United States and Canada found that 22% of people using GLP-1 medications wanted hydration and electrolyte support, while 27% sought benefits for digestion and gut health. Concerns about possible side effects contributed to those priorities. Melanie Croce, principal designer, Re-Imagine Wellness IC&D at IFF Taste, said that people taking these medicines often consume less food and drink, increasing the importance of the hydration, protein, micronutrients and other functional benefits supplied by each serving. IFF’s GLP-1 Consumer Moments of Opportunity report sets out a framework called “Hydration Plus”, which examines both the physical needs and emotional purposes associated with drinking. It recommends beginning product development with the particular consumer need a beverage will address.
The framework describes five occasions for hydration products. “Replenish” covers recovery and fluid replacement, with possible formulations using electrolytes and refreshing fruit flavours. “Maintain” concerns routine hydration, supported by convenient packaging formats and suitable sweetness. “Vitality” involves supplying particular vitamins and minerals, whereas “Perform” covers consumption associated with mental or physical demands. The fifth category, “Connect”, addresses familiar drinking rituals and occasions shared with other people. Croce said nutritional benefits and enjoyment need to be developed together, with the sensory characteristics matched to the occasion in which a drink is consumed.
According to Croce, smaller portions leave less tolerance for unpleasant textures or an aftertaste that persists. A drink intended to provide morning nutrition may need a different combination of flavour and texture from an indulgent product or one consumed in the evening to supplement nutrient intake. Reported sensory experiences among GLP-1 users differ: some describe stronger or weaker responses to sweetness, or unfamiliar bitter and metallic sensations. Others notice shifts in appetite or food preferences without detecting changes in their basic ability to taste. Croce said manufacturers therefore need to account for differences between consumers when designing sensory profiles.
IFF lists overpowering aromas, excessive sweetness, gritty or chalk-like textures and persistent aftertastes among possible causes of dissatisfaction. Ingredients added for functional purposes can introduce bitter or mineral flavours and unwanted sensations in the mouth. Innova found natural flavours in 57% of launches making GLP-1-friendly claims. Its US research also found that 56% of GLP-1 users said they had been treating themselves to indulgent foods more frequently after beginning medication. The finding covered food consumption overall. These results sit alongside manufacturers’ work on combining nutritional functionality with products consumers enjoy drinking.
Croce recommends building flavours around a beverage’s intended nutritional benefits, rather than relying only on concealment of undesirable notes. She described an approach in which the flavour makes the added functionality feel like a deliberate part of the product. Modulation techniques can adjust flavour balance, mouthfeel and the broader drinking experience. IFF says its FLAVORFIT™ range is designed to optimise the sensory characteristics of finished beverages. The company presents this work as part of formulation development that addresses taste and texture alongside the ingredients used to deliver functional benefits.
Protein addition brings further technical requirements. Croce highlighted the difficulty of incorporating protein into acidic, carbonated beverages while preserving clarity, stability and the desired texture. Formulators must select appropriate proteins, use stabilisation systems and adjust both flavour and mouthfeel. She said the nutritional requirements and preferences of consumers using GLP-1 treatments differ, requiring more than one formulation approach. Protein-fortified products are among the areas manufacturers are exploring for consumers seeking additional nutrition from drinks.
A review published in Frontiers in Nutrition in 2026 examined the evidence on GLP-1 medications and taste. It found that available research did not demonstrate a consistent deterioration in basic taste function. The review called for distinguishing sensory changes from changes in the enjoyment of food and the motivation to eat. Although these medicines have been associated with altered appetite and eating behaviour, the review described their effects on taste perception as less clear.
